WuXi AppTec provides integrated, end-to-end drug discovery and manufacturing services to the global pharmaceutical and life sciences industries, with operations in Asia, Europe and North America. Through its unique “CRDMO” and “CTDMO” business models, WuXi AppTec continuously lowers the threshold of R&D, helps clients improve R&D efficiency, and brings more breakthrough therapeutic solutions to patients, with services ranging from chemical R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, precision medicine, and biotechnology, biological research, preclinical testing and clinical trial R&D, precision medicine R&D, testing and manufacturing, etc. In 2023, WuXi PharmaTech was rated AA in ESG (Environmental, Social and Governance) by MSCI for the third consecutive year. Currently, the company's empowerment platform is carrying the R&D and innovation projects of more than 6,000 partners from more than 30 countries around the world, and is committed to bringing more new and better medicines to patients around the globe and realizing the vision of “making the world free of hard-to-make medicines and hard-to-treat diseases” as soon as possible.